Debt-to-equity in % of Coherus Oncology, Inc. from Q2 2015 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Coherus Oncology, Inc. quarterly Debt-to-equity history and change rate from Q2 2015 to Q3 2025.
  • Coherus Oncology, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was -1.75K %, a 159% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Coherus Oncology, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 -1.75K -1.07K -159% 30 Sep 2025
Q2 2025 -722 -84.1 -13.2% 30 Jun 2025
Q1 2025 -510 +9.08 +1.75% 31 Mar 2025
Q4 2024 -720 -321 -80.6% 31 Dec 2024
Q3 2024 -675 -274 -68.2% 30 Sep 2024
Q2 2024 -638 -224 -54% 30 Jun 2024
Q1 2024 -519 +17.3 +3.22% 31 Mar 2024
Q4 2023 -399 +589 +59.6% 31 Dec 2023
Q3 2023 -402 +24.7K +98.4% 30 Sep 2023
Q2 2023 -414 -1.49K -139% 30 Jun 2023
Q1 2023 -536 -1.13K -190% 31 Mar 2023
Q4 2022 -988 -1.44K -316% 31 Dec 2022
Q3 2022 -25.1K -25.4K -7628% 30 Sep 2022
Q2 2022 1.07K +797 +290% 30 Jun 2022
Q1 2022 593 +341 +135% 31 Mar 2022
Q4 2021 457 +241 +111% 31 Dec 2021
Q3 2021 334 +101 +43.2% 30 Sep 2021
Q2 2021 275 30 Jun 2021
Q1 2021 253 31 Mar 2021
Q4 2020 216 31 Dec 2020
Q3 2020 233 30 Sep 2020
Q4 2018 1.49K +1.21K +426% 31 Dec 2018
Q3 2018 498 +184 +58.9% 30 Sep 2018
Q2 2018 354 -19.2 -5.14% 30 Jun 2018
Q1 2018 461 -647 -58.4% 31 Mar 2018
Q4 2017 284 +1.54K 31 Dec 2017
Q3 2017 313 +1.3K 30 Sep 2017
Q2 2017 374 +1.44K 30 Jun 2017
Q1 2017 1.11K -163 -12.8% 31 Mar 2017
Q4 2016 -1.26K -1.64K -428% 31 Dec 2016
Q3 2016 -984 -1.21K -533% 30 Sep 2016
Q2 2016 -1.07K -2.09K -205% 30 Jun 2016
Q1 2016 1.27K 31 Mar 2016
Q4 2015 384 31 Dec 2015
Q3 2015 227 30 Sep 2015
Q2 2015 1.02K 30 Jun 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.